Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Plavix
Plavix 75 mg film-coated tablets Plavix 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-087943 · Präparat HOS-083591
Medicinal products that are strong or moderate CYP2C19 inhibitors include, for example, omeprazole
and esomeprazole, fluvoxamine, fluoxetine, moclobemide, voriconazole, fluconazole, ticlopidine,
carbamazepine, and efavirenz.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): esomeprazole (HOS-087944) carbamazepine (HOS-085618) moclobemide (HOS-087879) voriconazole (HOS-084524) fluconazole (HOS-087945) fluoxetine (HOS-085946) efavirenz (HOS-087947) fluvoxamine (HOS-085908) ticlopidine (HOS-087946) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-14T12:15:00Z · SHA-256 1e6a9d1e2861882ccf51f6506686a24b3c88e112fad66a7a9333c6e88547592c · Passage 6adad8692c6fecb943bf126bdc5047021725d2d6aca1b2738e493857127bf04c · Zeichen 4217–4441 im Abschnitt
Wechselwirkungen · Iscover
Iscover 75 mg film-coated tablets Iscover 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-087998 · Präparat HOS-083599
Medicinal products that are strong or moderate CYP2C19 inhibitors include, for example, omeprazole
and esomeprazole, fluvoxamine, fluoxetine, moclobemide, voriconazole, fluconazole, ticlopidine,
carbamazepine, and efavirenz.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): esomeprazole (HOS-087944) carbamazepine (HOS-085618) moclobemide (HOS-087879) voriconazole (HOS-084524) fluconazole (HOS-087945) fluoxetine (HOS-085946) efavirenz (HOS-087947) fluvoxamine (HOS-085908) ticlopidine (HOS-087946) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-26T11:41:00Z · SHA-256 3fe5799ec5f9f1d2b848168c6cfaf56d702c6bce3141e7d7aa95ef81abbc8acc · Passage 6adad8692c6fecb943bf126bdc5047021725d2d6aca1b2738e493857127bf04c · Zeichen 4216–4440 im Abschnitt
Wechselwirkungen · Viramune
Viramune 200 mg tablets · Abschnitt 4.5 · PDF-Seite 13
HOS-088116 · Präparat HOS-083615
ANTIFUNGALS
Fluconazole Fluconazole AUC 0.94 Because of the risk of increased
200 mg QD (0.88-1.01) exposure to Viramune, caution
Fluconazole Cmin 0.93 should be exercised if the
(0.86-1.01) medicinal products are given
Fluconazole Cmax 0.92 concomitantly and patients should
(0.85-0.99) be monitored closely.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fluconazole (HOS-087945)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage a3697aff8b39914d8bb70d99da7a82dd2195696599d4526e57ae6f3b1a48f34c · Zeichen 16873–17407 im Abschnitt
Wechselwirkungen · Viramune
Viramune 50 mg/5 mL oral suspension · Abschnitt 4.5 · PDF-Seite 37–38
HOS-088213 · Präparat HOS-083615
37
ANTIFUNGALS
Fluconazole Fluconazole AUC 0.94 Because of the risk of increased
200 mg QD (0.88-1.01) exposure to Viramune, caution
Fluconazole Cmin 0.93 should be exercised if the
(0.86-1.01) medicinal products are given
Fluconazole Cmax 0.92 concomitantly and patients should
(0.85-0.99) be monitored closely.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fluconazole (HOS-087945)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage 29bfe847dbafd53d8e04cc8bd0839e23a5ab754d34ecb1d2431c674bb4cb6f39 · Zeichen 16884–17464 im Abschnitt
Wechselwirkungen · Viramune
Viramune 400 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 63
HOS-088305 · Präparat HOS-083615
ANTIFUNGALS
Fluconazole Fluconazole AUC 0.94 Because of the risk of increased
200 mg QD (0.88-1.01) exposure to Viramune, caution
Fluconazole Cmin 0.93 should be exercised if the
(0.86-1.01) medicinal products are given
Fluconazole Cmax 0.92 concomitantly and patients should
(0.85-0.99) be monitored closely.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fluconazole (HOS-087945)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage a3697aff8b39914d8bb70d99da7a82dd2195696599d4526e57ae6f3b1a48f34c · Zeichen 17093–17627 im Abschnitt
Wechselwirkungen · Combivir
Combivir 150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7–8
HOS-088514 · Präparat HOS-083663
7
sulfamethoxazole for the
treatment of Pneumocystis
jirovecii pneumonia (PCP) and
toxoplasmosis have not been
studied and should be avoided.
ANTIFUNGALS
Fluconazole/Lamivudine Interaction not studied. As only limited data are
Fluconazole/Zidovudine Zidovudine AUC 74% available the clinical
(400 mg once daily/200 mg significance is not known.
thrice daily) (UGT inhibition) Monitor for signs of
zidovudine toxicity (see
section 4.8).
ANTIMYCOBACTERIALS
Rifampicin/Lamivudine Interaction not studied. Insufficient data to
Rifampicin/Zidovudine (600 Zidovudine AUC 48% recommend dosage
mg once daily/200 mg thrice adjustment.
daily) (UGT induction)
ANTICONVULSANTS
Phenobarbital/Lamivudine Interaction not studied. Insufficient data to
Phenobarbital/Zidovudine Interaction not studied. recommend dosage
adjustment.
Potential to slightly decrease
zidovudine plasma
concentrations through UGT
induction.
Phenytoin/Lamivudine Interaction not studied. Monitor phenytoin
Phenytoin/Zidovudine Phenytoin AUC concentrations.
Valproic acid/Lamivudine Interaction not studied. As only limited data are
Valproic acid/Zidovudine Zidovudine AUC 80% available the clinical
(250 mg or 500 mg thrice significance is not known.
daily/100 mg thrice daily)
(UGT inhibition) Monitor for signs of
zidovudine toxicity (see
section 4.8).
ANTIHISTAMINES (HISTAMINE H1 RECEPTOR ANTAGONISTS)
Ranitidine/Lamivudine Interaction not studied. No dosage adjustment
necessary.
Clinically significant
interaction unlikely. Ranitidine
eliminated only in part by renal
organic cation transport system.
Ranitidine/Zidovudine Interaction not studied
Cimetidine/Lamivudine Interaction not studied. No dosage adjustment
necessary.
Clinically significant
interaction unlikely.
Cimetidine eliminated only in
part by renal organic cation
transport system.
Cimetidine/Zidovudine Interaction not studied.
CYTOTOXICS
Cladribine/Lamivudine Interaction not studied Therefore the concomitant use
of lamivudine with cladribine
In vitro lamivudine inhibits the is not recommended
intracellular phosphorylation of (see section 4.4)
cladribine leading to a potential
risk of cladribine loss of
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) phenobarbital (HOS-085617) valproic acid (HOS-088515) cimetidine (HOS-085835) histamine (HOS-088516) fluconazole (HOS-087945) ranitidine (HOS-085660) phenytoin (HOS-084531) cladribine (HOS-085842)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-29T01:24:00Z · SHA-256 4660d55c0813c2571a95614bba44492fff03e6854bbe956eb43509fe476e679d · Passage 80bfcdbc676c074809992c973802a382b624f4a50bfeaaede637578173acc0cf · Zeichen 3740–7470 im Abschnitt
Wechselwirkungen · Rapamune
Rapamune 1 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 10
HOS-090616 · Präparat HOS-084095
Inhibitors of CYP3A4 may decrease the metabolism of sirolimus and increase sirolimus blood levels.
Such inhibitors include certain antifungals (e.g. clotrimazole, fluconazole, itraconazole, voriconazole),
certain antibiotics (e.g. troleandomycin, telithromycin, clarithromycin), certain protease inhibitors (e.g.
ritonavir, indinavir, boceprevir, telaprevir), nicardipine, bromocriptine, cimetidine, danazol and
letermovir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) letermovir (HOS-090621) nicardipine (HOS-090619) protease (HOS-085623) cimetidine (HOS-085835) clotrimazole (HOS-090574) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) itraconazole (HOS-084516) danazol (HOS-085473) fluconazole (HOS-087945) boceprevir (HOS-090617) clarithromycin (HOS-084517) troleandomycin (HOS-090575) bromocriptine (HOS-090620) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-04T09:34:00Z · SHA-256 822914cb553b9bcf81064d714c9274d63e73d083445521dca5c314d6106f24d7 · Passage 5e78d73fd3b12aea3ede2eeac1a14a3dfb8e863d7c5ea6929177114d000b7a9c · Zeichen 5491–5914 im Abschnitt
Wechselwirkungen · Rapamune
Rapamune 0.5 mg coated tablets Rapamune 1 mg coated tablets Rapamune 2 mg coated tablets · Abschnitt 4.5 · PDF-Seite 30
HOS-090685 · Präparat HOS-084095
Inhibitors of CYP3A4 may decrease the metabolism of sirolimus and increase sirolimus blood levels.
Such inhibitors include certain antifungals (e.g. clotrimazole, fluconazole, itraconazole, voriconazole),
certain antibiotics (e.g. troleandomycin, telithromycin, clarithromycin), certain protease inhibitors (e.g.
ritonavir, indinavir, boceprevir, and telaprevir), nicardipine, bromocriptine, cimetidine, danazol and
letermovir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) letermovir (HOS-090621) nicardipine (HOS-090619) protease (HOS-085623) cimetidine (HOS-085835) clotrimazole (HOS-090574) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) itraconazole (HOS-084516) danazol (HOS-085473) fluconazole (HOS-087945) boceprevir (HOS-090617) clarithromycin (HOS-084517) troleandomycin (HOS-090575) bromocriptine (HOS-090620) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-04T09:34:00Z · SHA-256 822914cb553b9bcf81064d714c9274d63e73d083445521dca5c314d6106f24d7 · Passage 238f7546225e192c0d4817ab6a1671062b9e93e1fd99e257fa0ce448f21b38a0 · Zeichen 5433–5860 im Abschnitt
Wechselwirkungen · Trizivir
TRIZIVIR 300 mg/150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-108562 · Präparat HOS-093047
ANTIFUNGALS
Fluconazole/Abacavir Interaction not studied. As only limited data are
Fluconazole/Lamivudine Interaction not studied. available the clinical
Fluconazole/Zidovudine Zidovudine AUC 74% significance is not known.
(400 mg once daily/200 mg Monitor for signs of
thrice daily) (UGT inhibition) zidovudine toxicity (see
section 4.8).
ANTIMYCOBACTERIALS
Rifampicin/Abacavir Interaction not studied. Insufficient data to
recommend dosage
Potential to slightly decrease adjustment.
abacavir plasma concentrations
through UGT induction.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fluconazole (HOS-087945)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T14:10:00Z · SHA-256 0fa44d429f9cace08dce2fd9d8c4f2ed838fc8cb0ed1b7cfc79bd6b9caa26349 · Passage c39632a3094bfdd22fcdfb5e2005478e6a40c7c5af3dcd5d71243b237e8b4d4b · Zeichen 4854–5772 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 25–26
HOS-108940 · Präparat HOS-093083
Methadone Methadone: ↓ Monitoring plasma concentrations
of methadone is recommended.
Oral contraceptives
Ethinyl Oestradiol Ethinyl Oestradiol: ↓ In case of co-administration of
Kaletra with contraceptives
containing ethinyl oestradiol
(whatever the contraceptive
formulation e.g. oral or patch),
additional methods of
contraception must be used.
Smoking cessation aids
Bupropion Buproprion and its active If the co-administration of Kaletra
metabolite, hydroxybupropion: with bupropion is judged
AUC and Cmax ↓ ~50% unavoidable, this should be done
under close clinical monitoring for
This effect may be due to bupropion efficacy, without
induction of bupropion exceeding the recommended
metabolism. dosage, despite the observed
induction.
Thyroid hormone replacement therapy
Levothyroxine Post-marketing cases have been Thyroid-stimulating hormone
reported indicating a potential (TSH) should be monitored in
interaction between ritonavir patients treated with levothyroxine
containing products and at least the first month after
levothyroxine. starting and/or ending
lopinavir/ritonavir treatment.
Vasodilating agents
25
Bosentan Lopinavir - ritonavir: Caution should be exercised in
Lopinavir/ritonavir plasma administering Kaletra with
concentrations may decrease due bosentan.
to CYP3A4 induction by When Kaletra is administered
bosentan. concomitantly with bosentan, the
efficacy of the HIV therapy should
Bosentan: be monitored and patients should
AUC: ↑ 5-fold be closely observed for bosentan
Cmax: ↑ 6-fold toxicity, especially during the first
Initially, bosentan Cmin: ↑ by week of co-administration.
approximately 48-fold.
Due to CYP3A4 inhibition by
lopinavir/ritonavir.
Riociguat Serum concentrations may be The co-administration of riociguat
increased due to CYP3A and with Kaletra is not recommended
P-gp inhibition by (see section 4.4 and refer to
lopinavir/ritonavir. riociguat SmPC).
Other medicinal products
Based on known metabolic profiles, clinically significant interactions are not expected between
Kaletra and dapsone, trimethoprim/sulfamethoxazole, azithromycin or fluconazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) bupropion (HOS-086329) riociguat (HOS-086293) methadone (HOS-086198) trimethoprim (HOS-085184) azithromycin (HOS-088112) fluconazole (HOS-087945) bosentan (HOS-086291) dapsone (HOS-088141) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 8d752c4274572732732b0956ff6ff26c5cf23921c5ef2d225aedad5e185afa6d · Zeichen 59817–63890 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 61
HOS-109024 · Präparat HOS-093083
Thyroid hormone replacement therapy
Levothyroxine Post-marketing cases have been Thyroid-stimulating hormone (TSH)
reported indicating a potential should be monitored in patients
interaction between ritonavir treated with levothyroxine at least the
containing products and first month after starting and/or
levothyroxine. ending lopinavir/ritonavir treatment.
Vasodilating agents
Bosentan Lopinavir - ritonavir: Caution should be exercised in
Lopinavir/ritonavir plasma administering Kaletra with bosentan.
concentrations may decrease due When Kaletra is administered
to CYP3A4 induction by concomitantly with bosentan, the
bosentan. efficacy of the HIV therapy should
be monitored and patients should be
Bosentan: closely observed for bosentan
AUC: ↑ 5-fold toxicity, especially during the first
Cmax: ↑ 6-fold week of co-administration.
Initially, bosentan Cmin: ↑ by
approximately 48-fold.
Due to CYP3A4 inhibition by
lopinavir/ritonavir.
Riociguat Serum concentrations may be The co-administration of riociguat
increased due to CYP3A and P-gp with Kaletra is not recommended
inhibition by lopinavir/ritonavir. (see section 4.4 and refer to riociguat
SmPC).
Other medicinal products
Based on known metabolic profiles, clinically significant interactions are not expected between
Kaletra and dapsone, trimethoprim/sulfamethoxazole, azithromycin or fluconazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) riociguat (HOS-086293) trimethoprim (HOS-085184) azithromycin (HOS-088112) fluconazole (HOS-087945) bosentan (HOS-086291) dapsone (HOS-088141) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 65f5a6f4d7302840533b08e744ce8d52c7c6cce98bf349aa71cfb302b25446dd · Zeichen 59068–61276 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 96–97
HOS-109102 · Präparat HOS-093083
96
Oral contraceptives
Ethinyl Oestradiol Ethinyl Oestradiol: ↓ In case of co-administration of
Kaletra with contraceptives
containing ethinyl oestradiol
(whatever the contraceptive
formulation e.g. oral or patch),
additional methods of contraception
must be used.
Smoking cessation aids
Bupropion Buproprion and its active If the co-administration of Kaletra
metabolite, hydroxybupropion: with bupropion is judged
AUC and Cmax ↓ ~50% unavoidable, this should be done
under close clinical monitoring for
This effect may be due to bupropion efficacy, without
induction of bupropion exceeding the recommended
metabolism. dosage, despite the observed
induction.
Thyroid hormone replacement therapy
Levothyroxine Post-marketing cases have been Thyroid-stimulating hormone
reported indicating a potential (TSH) should be monitored in
interaction between ritonavir patients treated with levothyroxine
containing products and at least the first month after starting
levothyroxine. and/or ending lopinavir/ritonavir
treatment.
Vasodilating agents
Bosentan Lopinavir - ritonavir: Caution should be exercised in
Lopinavir/ritonavir plasma administering Kaletra with
concentrations may decrease due bosentan.
to CYP3A4 induction by When Kaletra is administered
bosentan. concomitantly with bosentan, the
efficacy of the HIV therapy should
Bosentan: be monitored and patients should be
AUC: ↑ 5-fold closely observed for bosentan
Cmax: ↑ 6-fold toxicity, especially during the first
Initially, bosentan Cmin: ↑ by week of coadministration.
approximately 48-fold.
Due to CYP3A4 inhibition by
lopinavir/ritonavir.
Riociguat Serum concentrations may be The co-administration of riociguat
increased due to CYP3A and with Kaletra is not recommended
P-gp inhibition by (see section 4.4 and refer to
lopinavir/ritonavir. riociguat SmPC).
Other medicinal products
Based on known metabolic profiles, clinically significant interactions are not expected between
Kaletra and dapsone, trimethoprim/sulfamethoxazole, azithromycin or fluconazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) bupropion (HOS-086329) riociguat (HOS-086293) trimethoprim (HOS-085184) azithromycin (HOS-088112) fluconazole (HOS-087945) bosentan (HOS-086291) dapsone (HOS-088141) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage eb717f7573e257a0db9660c2692fa6be3f81b8ac5b4c1043b1f49219b74ffa31 · Zeichen 58967–62731 im Abschnitt
Wechselwirkungen · Dynastat
Dynastat 40 mg powder for solution for injection · Abschnitt 4.5 · PDF-Seite 7
HOS-109358 · Präparat HOS-093187
Plasma exposure (AUC and Cmax) to valdecoxib was increased (62% and 19%, respectively) when
coadministered with fluconazole (predominantly a CYP2C9 inhibitor), indicating that the dose of
parecoxib should be reduced in those patients who are receiving fluconazole therapy.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fluconazole (HOS-087945) valdecoxib (HOS-109357)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T17:26:00Z · SHA-256 a94a02bdad229376a395299eccbc2ab09dd742598fb29796b8e5ada490a65e06 · Passage 1e75319ebfb1622b4b39821cfdfd9a2b75211001b4479cf41519f8dca7f7c3da · Zeichen 2974–3246 im Abschnitt
Wechselwirkungen · Dynastat
Dynastat 40 mg powder and solvent for solution for injection · Abschnitt 4.5 · PDF-Seite 23
HOS-109405 · Präparat HOS-093187
Plasma exposure (AUC and Cmax) to valdecoxib was increased (62% and 19%, respectively) when
coadministered with fluconazole (predominantly a CYP2C9 inhibitor), indicating that the dose of
parecoxib should be reduced in those patients who are receiving fluconazole therapy.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fluconazole (HOS-087945) valdecoxib (HOS-109357)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T17:26:00Z · SHA-256 a94a02bdad229376a395299eccbc2ab09dd742598fb29796b8e5ada490a65e06 · Passage 1e75319ebfb1622b4b39821cfdfd9a2b75211001b4479cf41519f8dca7f7c3da · Zeichen 2976–3248 im Abschnitt
Wechselwirkungen · Vfend
VFEND 50 mg film-coated tablets VFEND 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12–13
HOS-109458 · Präparat HOS-093201
300 mg QD (coadministered Phenytoin Cmax 67% Phenytoin may be
with voriconazole 400 mg Phenytoin AUC 81% coadministered with
BID)* Compared to voriconazole 200 mg voriconazole if the maintenance
BID, dose of voriconazole is increased
Voriconazole Cmax 34% to 5 mg/kg IV BID or from
Voriconazole AUC 39% 200 mg to 400 mg oral BID
(100 mg to 200 mg oral BID in
patients less than 40 kg) (see
section 4.2).
12
Antidiabetics
Sulfonylureas (including but Although not studied, voriconazole Careful monitoring of blood
not limited to: tolbutamide, is likely to increase the plasma glucose is recommended. Dose
glipizide, glyburide) concentrations of sulfonylureas and reduction of sulfonylureas should
[CYP2C9 substrates] cause hypoglycaemia. be considered.
Anti-fungals
Fluconazole (200 mg QD) Voriconazole Cmax 57% The reduced dose and/or
[CYP2C9, CYP2C19 and Voriconazole AUC 79% frequency of voriconazole and
CYP3A4 inhibitor] Fluconazole Cmax ND fluconazole that would eliminate
Fluconazole AUC ND this effect have not been
established. Monitoring for
voriconazole-associated adverse
reactions is recommended if
voriconazole is used sequentially
after fluconazole.
Antihistamines
Astemizole Although not studied, increased Contraindicated (see section
[CYP3A4 substrate] plasma concentrations of 4.3)
astemizole can lead to QTc
prolongation and rare occurrences
of torsades de pointes.
Terfenadine Although not studied, increased Contraindicated (see section
[CYP3A4 substrate] plasma concentrations of 4.3)
terfenadine can lead to QTc
prolongation and rare occurrences
of torsades de pointes.
Anti HIV agents
Indinavir (800 mg TID) Indinavir Cmax ↔ No dose adjustment
[CYP3A4 inhibitor and Indinavir AUC ↔
substrate] Voriconazole Cmax ↔
Voriconazole AUC ↔
Ritonavir (protease inhibitor)
[potent CYP450 inducer;
CYP3A4 inhibitor and
substrate]
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): glipizide (HOS-109460) indinavir (HOS-084518) protease (HOS-085623) glucose (HOS-088412) lead (HOS-085592) glyburide (HOS-109273) fluconazole (HOS-087945) astemizole (HOS-085608) ritonavir (HOS-084521) terfenadine (HOS-085607) phenytoin (HOS-084531) tolbutamide (HOS-086568)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage c43ce720ce152b6ffc284ecb767edcbe81187c3aba91372adac27d1baca516f9 · Zeichen 11584–14886 im Abschnitt
Wechselwirkungen · Vfend
VFEND 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 44
HOS-109539 · Präparat HOS-093201
300 mg QD (coadministered Phenytoin Cmax 67% Phenytoin may be
with voriconazole 400 mg Phenytoin AUC 81% coadministered with
BID)* Compared to voriconazole 200 mg voriconazole if the maintenance
BID, dose of voriconazole is increased
Voriconazole Cmax 34% to 5 mg/kg IV BID or from
Voriconazole AUC 39% 200 mg to 400 mg oral BID
(100 mg to 200 mg oral BID in
patients less than 40 kg) (see
section 4.2).
Antidiabetics
Sulfonylureas (including but Although not studied, voriconazole Careful monitoring of blood
not limited to: tolbutamide, is likely to increase the plasma glucose is recommended. Dose
glipizide, glyburide) concentrations of sulfonylureas and reduction of sulfonylureas should
[CYP2C9 substrates] cause hypoglycaemia. be considered.
Anti-fungals
Fluconazole (200 mg QD) Voriconazole Cmax 57% The reduced dose and/or
[CYP2C9, CYP2C19 and Voriconazole AUC 79% frequency of voriconazole and
CYP3A4 inhibitor] Fluconazole Cmax ND fluconazole that would eliminate
Fluconazole AUC ND this effect have not been
established. Monitoring for
voriconazole-associated adverse
reactions is recommended if
voriconazole is used sequentially
after fluconazole.
Antihistamines
Astemizole Although not studied, increased Contraindicated (see section
[CYP3A4 substrate] plasma concentrations of 4.3)
astemizole can lead to QTc
prolongation and rare occurrences
of torsades de pointes.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): glipizide (HOS-109460) glucose (HOS-088412) lead (HOS-085592) glyburide (HOS-109273) fluconazole (HOS-087945) astemizole (HOS-085608) phenytoin (HOS-084531) tolbutamide (HOS-086568)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 14b5c619fb8c5577b3bdbf58510949a3e586575fc62bef1b01af9d0042239698 · Zeichen 11998–14502 im Abschnitt
Wechselwirkungen · Vfend
VFEND 40 mg/ml powder for oral suspension · Abschnitt 4.5 · PDF-Seite 76–77
HOS-109604 · Präparat HOS-093201
300 mg QD (coadministered Phenytoin Cmax 67% Phenytoin may be
with voriconazole 400 mg Phenytoin AUC 81% coadministered with
BID)* Compared to voriconazole 200 mg voriconazole if the maintenance
BID, dose of voriconazole is increased
Voriconazole Cmax 34% to 5 mg/kg IV BID or from
Voriconazole AUC 39% 200 mg to 400 mg oral BID
(100 mg to 200 mg oral BID in
patients less than 40 kg) (see
section 4.2).
76
Antidiabetics
Sulfonylureas (including but Although not studied, voriconazole Careful monitoring of blood
not limited to: tolbutamide, is likely to increase the plasma glucose is recommended. Dose
glipizide, glyburide) concentrations of sulfonylureas and reduction of sulfonylureas should
[CYP2C9 substrates] cause hypoglycaemia. be considered.
Anti-fungals
Fluconazole (200 mg QD) Voriconazole Cmax 57% The reduced dose and/or
[CYP2C9, CYP2C19 and Voriconazole AUC 79% frequency of voriconazole and
CYP3A4 inhibitor] Fluconazole Cmax ND fluconazole that would eliminate
Fluconazole AUC ND this effect have not been
established. Monitoring for
voriconazole-associated adverse
reactions is recommended if
voriconazole is used sequentially
after fluconazole.
Antihistamines
Astemizole Although not studied, increased Contraindicated (see section
[CYP3A4 substrate] plasma concentrations of 4.3)
astemizole can lead to QTc
prolongation and rare occurrences
of torsades de pointes.
Terfenadine Although not studied, increased Contraindicated (see section
[CYP3A4 substrate] plasma concentrations of 4.3)
terfenadine can lead to QTc
prolongation and rare occurrences
of torsades de pointes.
Anti HIV agents
Indinavir (800 mg TID) Indinavir Cmax ↔ No dose adjustment
[CYP3A4 inhibitor and Indinavir AUC ↔
substrate] Voriconazole Cmax ↔
Voriconazole AUC ↔
Ritonavir (protease inhibitor)
[potent CYP450 inducer;
CYP3A4 inhibitor and
substrate]
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): glipizide (HOS-109460) indinavir (HOS-084518) protease (HOS-085623) glucose (HOS-088412) lead (HOS-085592) glyburide (HOS-109273) fluconazole (HOS-087945) astemizole (HOS-085608) ritonavir (HOS-084521) terfenadine (HOS-085607) phenytoin (HOS-084531) tolbutamide (HOS-086568)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage f19ccc38aa29c7c75168a00762b93a1ec1fb9ac13e31bd781df6a45a736467a1 · Zeichen 11616–14918 im Abschnitt
Wechselwirkungen · Tracleer
Tracleer 62.5 mg film-coated tablets Tracleer 125 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-109922 · Präparat HOS-093279
Fluconazole and other inhibitors of both CYP2C9 and CYP3A4: Co-administration with fluconazole,
which inhibits mainly CYP2C9, but to some extent also CYP3A4, could lead to large increases in
plasma concentrations of bosentan. The combination is not recommended. For the same reason,
concomitant administration of both a potent CYP3A4 inhibitor (such as ketoconazole, itraconazole or
ritonavir) and a CYP2C9 inhibitor (such as voriconazole) with Tracleer is not recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) voriconazole (HOS-084524) lead (HOS-085592) itraconazole (HOS-084516) fluconazole (HOS-087945) ritonavir (HOS-084521) bosentan (HOS-086291)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-25T15:01:00Z · SHA-256 eddfcd40df26bd01c2c7847da53c544c94e0bafb8bcc62374b5c7788669470bc · Passage f0f8a00a013cf8d3c79a39ec409d4ac945f15268559ebbcad8f852840ca7a673 · Zeichen 851–1324 im Abschnitt
Wechselwirkungen · Tracleer
Tracleer 32 mg dispersible tablets · Abschnitt 4.5 · PDF-Seite 31
HOS-109975 · Präparat HOS-093279
Fluconazole and other inhibitors of both CYP2C9 and CYP3A4: Co-administration with fluconazole,
which inhibits mainly CYP2C9, but to some extent also CYP3A4, could lead to large increases in
plasma concentrations of bosentan. The combination is not recommended. For the same reason,
concomitant administration of both a potent CYP3A4 inhibitor (such as ketoconazole, itraconazole or
ritonavir) and a CYP2C9 inhibitor (such as voriconazole) with Tracleer is not recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) voriconazole (HOS-084524) lead (HOS-085592) itraconazole (HOS-084516) fluconazole (HOS-087945) ritonavir (HOS-084521) bosentan (HOS-086291)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-25T15:01:00Z · SHA-256 eddfcd40df26bd01c2c7847da53c544c94e0bafb8bcc62374b5c7788669470bc · Passage f0f8a00a013cf8d3c79a39ec409d4ac945f15268559ebbcad8f852840ca7a673 · Zeichen 794–1267 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 14
HOS-112084 · Präparat HOS-093615
In the majority of patients with at least one Therefore if the combination is
functional CYP2C19 allele, a reduction in unavoidable, the following
both voriconazole and atazanavir recommendations are made
exposures are expected. according to the CYP2C19 status:
Voriconazole 50 mg twice daily Voriconazole AUC: ↑561% (↑451% - in patients with at least one
(atazanavir 300 mg/ritonavir ↑699%) functional CYP2C19 allele,
100 mg once daily) Voriconazole Cmax: ↑438% (↑355% close clinical monitoring for
↑539%) a loss of both voriconazole
Subjects without a functional Voriconazole Cmin: ↑765% (↑571% (clinical signs) and
CYP2C19 allele. ↑1,020%) atazanavir (virologic
response) efficacy is
Atazanavir AUC: ↓20% (↓35% ↓3%) recommended.
Atazanavir Cmax: ↓19% (↓34% ↔0.2%)
Atazanavir Cmin: ↓31% (↓46% ↓13%) - in patients without a
functional CYP2C19 allele,
Ritonavir AUC: ↓11% (↓20% ↓1%) close clinical and laboratory
Ritonavir Cmax: ↓11% (↓24% ↑4%) monitoring of voriconazole-
Ritonavir Cmin: ↓19% (↓35% ↑1%) associated adverse events is
recommended.
In a small number of patients without a
functional CYP2C19 allele, significantly If genotyping is not feasible, full
increased voriconazole exposures are monitoring of safety and efficacy
expected. should be performed.
Fluconazole 200 mg once daily Atazanavir and fluconazole concentrations No dosage adjustments are needed
(atazanavir 300 mg and ritonavir were not significantly modified when for fluconazole and REYATAZ.
100 mg once daily) REYATAZ/ritonavir was co-administered
with fluconazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): voriconazole (HOS-084524) fluconazole (HOS-087945) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 5b65a42f774823c179b3ced81b86fa46cc1e0dc0e51f36c32727e82b04646898 · Zeichen 23769–26623 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.